An essential role for GLUT5-mediated fructose utilization in exacerbating the malignancy of clear cell renal cell carcinoma

  • Xing Jin
  • Yupei Liang
  • Dan Liu
  • Qin Luo
  • Lili Cai
  • Jia Wu
  • Lijun JiaEmail author
  • Wen-Lian ChenEmail author
Original Article


Fructose is an important alternative carbon source for several tumors, and GLUT5 is the major fructose transporter which mediates most of fructose uptake in cells. So far, it is unclear whether GLUT5-mediated fructose utilization is important for clear cell renal cell carcinoma (ccRCC). Here, we demonstrated that GLUT5 was highly expressed in a panel of ccRCC cell lines. High GLUT5 expression exacerbated the neoplastic phenotypes of ccRCC cells, including cell proliferation and colony formation. On the other hand, deletion of the GLUT5-encoding gene SLC2A5 dramatically attenuated cellular malignancy via activating the apoptotic pathway. Moreover, administration of 2,5-anhydro-D-mannitol (2,5-AM), a competitive inhibitor of fructose uptake, could markedly suppress ccRCC cell growth. Together, we provide a new mechanistic insight for GLUT5-mediated fructose utilization in ccRCC cells and highlight the therapeutic potential for targeting this metabolic pathway against ccRCC.


Clear cell renal cell carcinoma GLUT5 Fructose 


Author contributions

Conceptualization: L.J. and W.-L.C.; study supervision: L.J. and W.-L.C.; molecular and cellular experiments: X.J., Y.L., D.L., Q.L., L.C., and J.W.; statistical analysis: X.J. and Y.L.; writing—original draft: X.J.; writing—review & editing: L.J. and W.-L.C.


This study is supported by the Chinese Minister of Science and Technology grant (2016YFA0501800), National Natural Science Foundation of China (Grant Nos. 81625018, 81770147, 81802891), Program of Shanghai Academic/Technology Research Leader (18XD1403800), National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development (2017ZX09304001), The National Scientific and Technological Major Special Project of China (2018ZX09201008-002), Shanghai Rising-Star Program (18QA1404100), Research fund of Shanghai Municipal Commission of Health (20174Y0090), Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Shanghai Youth Talent Program, Gaofeng Clinical Medicine Grant of Shanghai Municipal Education Commission, and Xinling Scholar Program of Shanghai University of Traditional Chinese Medicine.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

Supplementary material

10565_2019_9478_MOESM1_ESM.docx (182 kb)
ESM 1 (DOCX 182 kb)


  1. Allard CB, Gelpi-Hammerschmidt F, Harshman LC, Choueiri TK, Faiena I, Modi P, et al. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Urol. Oncol. 2015;33(11):496 e11–6.Google Scholar
  2. Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J. Clin. 2017;67(6):507–24.Google Scholar
  3. Barone S, Fussell SL, Singh AK, Lucas F, Xu J, Kim C, et al. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J. Biol. Chem. 2009;284(8):5056–66.Google Scholar
  4. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015;17(4):351–9.Google Scholar
  5. Bu P, Chen KY, Xiang K, Johnson C, Crown SB, Rakhilin N, et al. Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metab. 2018;27(6):1249–1262 e4.Google Scholar
  6. Chen WL, Wang YY, Zhao A, Xia L, Xie G, Su M, et al. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell. 2016a;30(5):779–91.Google Scholar
  7. Chen P, Hu T, Liang Y, Li P, Chen X, Zhang J, et al. Neddylation inhibition activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5 axis in human esophageal cancer cells. Clin. Cancer Res. 2016b;22(16):4145–57.Google Scholar
  8. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.Google Scholar
  9. Curti BD. Immunotherapy in advanced renal cancer - is cure possible? N. Engl. J. Med. 2018;378(14):1344–5.Google Scholar
  10. Douard V, Ferraris RP. The role of fructose transporters in diseases linked to excessive fructose intake. J. Physiol. 2013;591(2):401–14.Google Scholar
  11. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7.Google Scholar
  12. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 2007;57(2):112–25.Google Scholar
  13. Ghatalia P, et al. Checkpoint inhibitors for the treatment of renal cell carcinoma. Curr. Treat. Options in Oncol. 2017;18(1):7.Google Scholar
  14. Gonzalez PS, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563(7733):719–23.Google Scholar
  15. Hamann I, Krys D, Glubrecht D, Bouvet V, Marshall A, Vos L, et al. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia. FASEB J. 2018;32(9):5104–18.Google Scholar
  16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.Google Scholar
  17. Heinzer H, Huland E, Huland H. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J. Urol. 2001;19(2):111–9.Google Scholar
  18. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551(7678):115–8.Google Scholar
  19. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113(9):2014–21.Google Scholar
  20. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 2016;375(18):1749–55.Google Scholar
  21. Keenan MM, Chi JT. Alternative fuels for cancer cells. Cancer J. 2015;21(2):49–55.Google Scholar
  22. Keshet R, Szlosarek P, Carracedo A, Erez A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat. Rev. Cancer. 2018;18(10):634–45.Google Scholar
  23. Kim YH, Jeong DC, Pak K, Han ME, Kim JY, Liangwen L, et al. SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget. 2017;8(40):68381–92.Google Scholar
  24. Klatte T, et al. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007;9(2):47–56.Google Scholar
  25. Korhonen M, Sariola H, Gould VE, Kangas L, Virtanen I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer Res. 1994;54(16):4532–8.Google Scholar
  26. Liu H, Huang D, McArthur DL, Boros LG, Nissen N, Heaney AP. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010;70(15):6368–76.Google Scholar
  27. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003;3(5):330–8.Google Scholar
  28. Masri S, Sassone-Corsi P. The emerging link between cancer, metabolism, and circadian rhythms. Nat. Med. 2018;24(12):1795–803.Google Scholar
  29. Medina Villaamil V, Aparicio Gallego G, Valbuena Rubira L, García Campelo R, Valladares-Ayerbes M, Grande Pulido E, et al. Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol. Rep. 2011;25(2):315–23.Google Scholar
  30. Momcilovic M, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33(5):905–921 e5.Google Scholar
  31. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996;335(12):865–75.Google Scholar
  32. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007;356(2):115–24.Google Scholar
  33. Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 2013;369(8):722–31.Google Scholar
  34. Motzer RJ, Tannir NM, McDermott D, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 2018;378(14):1277–90.Google Scholar
  35. Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol. Cell. 2017;67(4):685–701 e6.Google Scholar
  36. Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat. Rev. Cancer. 2016;16(10):663–73.Google Scholar
  37. Quinn DI, Lara PN Jr. Renal-cell cancer--targeting an immune checkpoint or multiple kinases. N. Engl. J. Med. 2015;373(19):1872–4.Google Scholar
  38. Rawson NE, Ji H, Friedman MI. 2,5-Anhydro-D-mannitol increases hepatocyte calcium: implications for a hepatic hunger stimulus. Biochim. Biophys. Acta. 2003;1642(1–2):59–66.Google Scholar
  39. Riquelme PT, Wernette-Hammond ME, Kneer NM, Lardy HA. Mechanism of action of 2,5-anhydro-D-mannitol in hepatocytes. Effects of phosphorylated metabolites on enzymes of carbohydrate metabolism. J. Biol. Chem. 1984;259(8):5115–23.Google Scholar
  40. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 2015;67(1):85–97.Google Scholar
  41. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017;67(1):7–30.Google Scholar
  42. Su C, Li H, Gao W. GLUT5 increases fructose utilization and promotes tumor progression in glioma. Biochem. Biophys. Res. Commun. 2018;500(2):462–9.Google Scholar
  43. Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat. Med. 2016;22(10):1108–19.Google Scholar
  44. Weng Y, et al. SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Cell Death Dis. 2018;4:38.Google Scholar
  45. Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, et al. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol. 2017;18(6):e341–53.Google Scholar
  46. Yonezawa Y, Nagashima Y, Sato H, Virgona N, Fukumoto K, Shirai S, et al. Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol. Carcinog. 2005;43(4):188–97.Google Scholar
  47. Zahoor H, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107.Google Scholar
  48. Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis. Gene. 2018;689:76–83.Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Cancer InstituteFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Cancer Institute, Longhua HospitalShanghai University of Traditional Chinese MedicineShanghaiChina
  3. 3.Department of Immunology, School of Basic Medical SciencesFudan UniversityShanghaiChina

Personalised recommendations